AcaHealth Pharma & Biotech Co.,LTD

[On Demand]
AcaHealth Pharma & Biotech Company was startup by Professor & Director Rong-Tsun Wu in 2009, derived from Research Center for Drug Discovery, National Yang-Ming University. Our company focus on:
1. Pure chemical drug discovery & development.
 US FDA approved AH-101-CVD for clinical trial(Chronic Heart Failure) in 2020 Jan.
 TFDA approved AH-101-CVD for clinical trial(Chronic Heart Failure) in 2020 Oct.
 We are ongoing Phase I Clinical Trial in Taipei Medical University Hospitals.
 We are ongoing AH-201-DE pre-IND meeting to TFDA for dry eye IND.
2.Botanical drug discovery & development.
3.High technology platform for producing active ingredients by plant tissue culture.

We focus on human experienced anti-aging-based drug discovery & development, aiming for unmet medical need especially aging related diseases such as chronic heart failure, chronic kidney disease, dry eye, neurodegenerative diseases, macular degeneration or insomnia.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
EH-201 for cardiovascular disease, chronic kidney disease, Anemia, dry eye
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 unlicensed global patents(cardiovascula, renal, anemia, dry eye, derivatives matter patents
President & CSO
AcaHealth Pharma & Biotech Co.,LTD